GleamWall
中文EN

ELUT ELUTIA INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1708527 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY5.2%
TTM net income YoY305.5%
TTM EPS YoY233.3%
Revenue 3-yr CAGR-26.9%
Net income 3-yr CAGR—

Margins

Gross margin59.0%
Operating margin-279.0%
Net margin546.7%
FCF margin-509.4%
EBITDA margin-265.2%

Returns

ROE—
ROA140.2%
ROIC (approx.)—
Asset turnover0.26x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.53x
Current ratio2.63x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.91x
Accruals ratio267.1%
Payout ratio—
Capex / revenue14.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.14M$2.43M$3.11M$3.27M$944,000$2.75M$2.95M$2.82M
Cost of revenue$435,000$980,000$1.31M$1.36M$446,000$1.29M$1.57M$1.49M
Gross profit$702,000$1.45M$1.80M$1.91M$498,000$1.45M$1.38M$1.32M
R&D expense$2.98M$2.53M$1.97M$1.22M$1.09M$989,000$871,000$727,000
SG&A expense$3.75M$3.45M$4.09M$4.29M$3.50M$3.55M$3.72M$4.25M
Operating income-$6.90M-$7.96M-$6.35M-$6.56M-$5.87M-$8.37M-$6.78M-$7.46M
Interest expense————$265,000$518,000$1.08M$1.07M
Pretax income-$6.50M-$7.64M-$7.82M-$6.52M-$1.04M-$7.08M-$1.88M-$7.15M
Income tax$8,000$8,000$70,000-$11,000$8,000$8,000$8,000$2,000
Net income-$1.28M-$7.65M-$7.47M$70.79M-$3.87M-$9.61M-$3.93M-$9.06M
EBITDA-$6.49M-$7.61M-$6.02M-$6.26M-$5.14M-$7.47M-$5.91M-$6.59M
EPS (basic)-0.03-0.17-0.17—-0.09-0.23-0.10—
EPS (diluted)-0.04-0.17-0.17—-0.19-0.26-0.21—
Weighted avg. shares (diluted)47.54M44.22M43.00M—46.96M46.31M42.91M—
Balance sheet
Cash & equivalents$29.09M$19.90M$28.49M$36.35M$4.72M$8.50M$17.36M$13.24M
Receivables$1.47M$1.44M$2.07M$1.73M$3.55M$3.15M$2.86M$2.28M
Inventory$272,000$2.65M$2.66M$438,000$2.01M$5.24M$4.29M$1.93M
Current assets$42.17M$37.22M$48.59M$55.82M$18.38M$22.28M$30.02M$26.17M
PP&E, net$2.83M$2.92M$2.91M$2.51M$2.05M$2.07M$1.03M$671,000
Intangibles$720,000$990,000$1.26M$1.53M$1.80M$6.58M$7.42M$2.60M
Total assets$48.19M$43.65M$55.21M$62.35M$29.41M$33.85M$39.30M$36.13M
Current liabilities$16.03M$21.05M$23.73M$25.14M$41.33M$37.95M$36.85M$37.80M
Short-term debt————$5.00M$3.75M$2.50M$1.25M
Long-term debt$8.10M———$21.10M$21.37M$21.76M$22.60M
Total debt$8.10M———$26.10M$25.12M$24.26M$23.85M
Total liabilities$32.87M$27.90M$32.68M$34.68M$73.33M$75.69M$75.76M$82.39M
Shareholders' equity$15.32M$15.75M$22.53M$27.67M-$43.92M-$41.84M-$36.46M-$46.26M
Net debt-$21.00M———$21.38M$16.62M$6.90M$10.61M
Cash flow statement
Operating cash flow-$8.13M-$8.46M-$7.83M-$24.81M-$2.89M-$8.23M-$8.88M-$12.26M
Capital expenditure$42,000$91,000$459,000$854,000$630,000$114,000$278,000$94,000
Free cash flow-$8.17M-$8.55M-$8.29M-$25.67M-$3.52M-$8.34M-$9.16M-$12.35M
Investing cash flow$7.66M-$91,000-$34,000$79.58M-$630,000-$114,000-$278,000-$94,000
Financing cash flow$9.67M-$40,000$3,000-$23.14M-$262,000-$516,000$13.28M-$151,000
Depreciation & amortization$403,000$349,000$330,000$297,000$728,000$892,000$868,000$863,000
Stock-based compensation$860,000$905,000$931,000$872,000$1.33M$1.03M$1.21M$1.21M

Free plan shows the latest 8 periods; Pro shows all 29 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.